Global Preeclampsia Diagnostics Market, Test Type (Blood Tests, Urine Analysis, and Others), By Product Type (Instruments and Consumables), By End User (Hospital, Specialty Clinics, Diagnostic Centers, and Others), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 1,270.1 Mn in 2021 and is expected to exhibit a CAGR of 11.8% during the forecast period (2021-2028), as highlighted in a new report published by Coherent Market Insights.
The Increasing prevalence of preeclampsia is expected to propel the growth of the global preeclampsia diagnostics market over the forecast period. For instance, according to the World Health Organization (WHO), the prevalence of preeclampsia is seven times higher in the emerging countries as compared to the developed countries. Also, as per a report by BioMed Central (BMC) in 2019, the incidence of preeclampsia ranges from 1.8% to 16.7% in the developing economies. It affects around 10% of pregnant women in the African continent every year.
Global Preeclampsia Diagnostics Market– Impact of Coronavirus (COVID-19) Pandemic
The COVID-19 pandemic has drastically affected clinical trials. Many trials have paused enrollment and researchers are facing multiple challenges associated with setting up remote visits, and performing laboratory and other study assessments. According to a survey conducted by Medidata Solutions, Inc. (a U.S.-based technology company, which develops and markets software as a service for clinical trials), on April 23, 2020, 63% of survey respondents reported that they stopped recruiting new patients for ongoing clinical trials and 43% of the respondents have postponed their studies. The U.S. Food and Drug Administration (FDA) released guidelines on conducting clinical trials of medical products during the COVID-19 public health emergency in March 2020. The guidelines were further updated on July 02, 2020. The guidelines issued by the U.S. Food and Drug Administration (FDA) include general considerations to assist sponsors and researchers, which ensure the safety of trial participants, and compliance with good clinical practice (GCP) for the duration of the COVID-19 public health emergency.
Browse 27 Market Data Tables and 31 Figures spread through 156 Pages and in-depth TOC on “Global Preeclampsia Diagnostics Market”- Forecast to 2028, Global Preeclampsia Diagnostics Market, Test Type (Blood Tests, Urine Analysis, and Others), By Product Type (Instruments and Consumables), By End User (Hospital, Specialty Clinics, Diagnostic Centers, and Others), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa).
To know the latest trends and insights prevalent in the Preeclampsia Diagnostics Market, click the link below:
https://www.coherentmarketinsights.com/market-insight/preeclampsia-diagnostics-market-4606
Moreover, key companies operating in market focusing on regulatory approvals for preeclampsia is also expected to aid in growth of the global preeclampsia diagnostics market over the forecast period. For instance, in June 2020, PerkinElmer received CE mark for its DELFIA Xpress sFlt-1 pre-eclampsia diagnostic kit. The blood test is designed for pregnant women in the second and third trimester. It measures the ratio of soluble Fms-like tyrosine-kinase-1 (sFlt-1). Abnormally high levels of the sFlt-1 protein have been linked to pre-eclampsia.
Key Takeaways of the Global Preeclampsia Diagnostics Market:
- The global preeclampsia diagnostics market is expected to exhibit a CAGR of 11.8% during the forecast period due to increasing research and development activities to innovate new tests to detect biomarkers indicating preeclampsia, which is expected to boost the market growth over the forecast period. For instance, in July 2020, researchers from the University of Helsinki have showed that HLA-G gene regulates male-to-female ratio at birth. The study strengthens earlier findings of the vulnerability of male fetuses to preeclampsia
- Among end user, diagnostic centers segment accounted for the largest market share in the global preeclampsia diagnostics market over the forecast period. Increasing prevalence of preeclampsia is expected to drive the segment growth over the forecast period. For instance, according to an article published in Medscape in 2018, it is clinically defined by hypertension and proteinuria, with or without pathologic edema. The incidence of preeclampsia in the U.S. is estimated to range from 2% to 6% in healthy, nulliparous women. Among all cases of the preeclampsia, 10% occur in pregnancies of less than 34 weeks' gestation.
- Among regions, North America accounted for the largest market share in the global preeclampsia diagnostics market over the forecast period. Increasing prevalence of preeclampsia to an increase in medical treatment cost among women with preeclampsia and their newborns, which is expected to drive the segment growth over the forecast period. For instance, according to the American Journal of Obstetrics and Gynecology (AJOG) in 2017, increasing the chance of adverse health outcomes, preeclampsia accounts for over US $2.18 billion of health care expenditure in the first 12 months after birth.
- Major players operating in the global preeclampsia diagnostics market are Diabetomics, Inc., Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, PerkinElmer Inc., Siemens Healthineers AG, DRG INSTRUMENTS GMBH, Metabolomic Diagnostics Ltd., Sera Prognostics, MOMM Diagnostics, Miraculins Inc.
